tiprankstipranks
Blueprint Medicines price target raised to $65 from $54 at Citi
PremiumThe FlyBlueprint Medicines price target raised to $65 from $54 at Citi
2M ago
Blueprint Medicines price target raised to $125 from $85 at H.C. Wainwright
PremiumThe Fly
Blueprint Medicines price target raised to $125 from $85 at H.C. Wainwright
2M ago
Blueprint Medicines price target raised to $99 from $90 at Oppenheimer
PremiumThe Fly
Blueprint Medicines price target raised to $99 from $90 at Oppenheimer
2M ago
Blueprint Medicines price target raised to $90 from $85 at Oppenheimer
PremiumThe FlyBlueprint Medicines price target raised to $90 from $85 at Oppenheimer
3M ago
Blueprint Medicines price target raised to $78 from $58 at Piper Sandler
PremiumThe Fly
Blueprint Medicines price target raised to $78 from $58 at Piper Sandler
3M ago
Blueprint Medicines says AYVAKIT has potential to be multibillion-dollar therapy
PremiumThe Fly
Blueprint Medicines says AYVAKIT has potential to be multibillion-dollar therapy
3M ago
Biotech Alert: Searches spiking for these stocks today
PremiumThe FlyBiotech Alert: Searches spiking for these stocks today
4M ago
Blueprint Medicines announces European Commission approval of AYVAKYT
PremiumThe Fly
Blueprint Medicines announces European Commission approval of AYVAKYT
4M ago
Oppenheimer Expects the S&P 500’s Advance to Continue Into 2024 — Here’s Why These 2 Stocks Might Be Worth Buying
PremiumStock Analysis & Ideas
Oppenheimer Expects the S&P 500’s Advance to Continue Into 2024 — Here’s Why These 2 Stocks Might Be Worth Buying
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100